
Vinorelbine Suppliers & Bulk Manufacturers
Available Forms: Intravenous Injection, Oral Capsule
Available Strengths: Injection: 10 mg/mL; Capsule : 20 mg, 30 mg, 40 mg
Reference Brands: Navelbine® , Alocrest (US & EU)
Category: Oncology Cancer Care
Vinorelbine is available in Intravenous Injection, Oral Capsule and strengths such as Injection: 10 mg/mL; Capsule : 20 mg, 30 mg, 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Vinorelbine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Vinorelbine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Vinorelbine, marketed as Navelbine®, is an essential chemotherapy agent used for the treatment of non-small cell lung cancer (NSCLC) and advanced breast cancer. Available as an intravenous injection and oral capsules, with strengths like 10 mg/mL (IV) and 20 mg, 30 mg, and 40 mg (oral), Vinorelbine inhibits cell division by disrupting microtubule formation. Widely sourced by B2B pharmaceutical suppliers, Vinorelbine is available globally, including in the US and EU. Manufactured under GMP standards, it provides reliable therapy options for hospitals and oncology centers fighting aggressive cancers.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers